AVXL ANAVEX LIFE SCIENCES CORP.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1314052 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY73.0%
TTM EPS YoY75.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-12.8%
ROA-11.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets6.4%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.25x
Accruals ratio14.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 | FY20212021-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $37.59M | $41.84M | $43.72M | $37.92M | $32.98M |
| SG&A expense | $13.82M | $11.04M | $12.05M | $13.07M | $9.02M |
| Operating income | -$51.41M | -$52.88M | -$55.76M | -$50.99M | -$42.00M |
| Pretax income | -$46.38M | -$43.00M | -$47.50M | -$47.62M | -$37.64M |
| Net income | -$46.38M | -$43.00M | -$47.51M | -$47.98M | -$37.91M |
| EPS (basic) | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 |
| EPS (diluted) | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 |
| Weighted avg. shares (diluted) | 85.29M | 83.47M | 79.79M | 76.91M | 69.80M |
| Banking | |||||
| Net interest income | $4.68M | $7.32M | $6.52M | $947,000 | $26,000 |
| Balance sheet | |||||
| Cash & equivalents | $102.58M | $132.19M | $151.02M | $149.16M | $152.11M |
| Total assets | $103.81M | $135.57M | $154.39M | $152.71M | $161.62M |
| Current liabilities | — | — | — | — | $10.80M |
| Total liabilities | $8.95M | $15.30M | $12.53M | $10.21M | $10.80M |
| Shareholders' equity | $94.87M | $120.26M | $141.85M | $142.49M | $150.82M |
| Shares outstanding | 86.67M | 84.80M | 82.07M | 77.94M | 75.92M |
| Cash flow statement | |||||
| Operating cash flow | -$39.04M | -$30.81M | -$27.79M | -$24.24M | -$30.38M |
| Financing cash flow | $9.43M | $11.97M | $29.65M | $21.29M | $153.24M |
| Stock-based compensation | $11.55M | $9.44M | $16.37M | $18.38M | $8.23M |
Free plan shows the latest 5 periods; Pro shows all 21 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.